Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ALEXION PHARMACEUTICALS, INC.

(ALXN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca runs into 'meaningful' investor revolt over pay

05/11/2021 | 12:45pm EDT
FILE PHOTO: Pascal Soriot, chief executive officer of pharmaceutical company AstraZeneca, attends an interview with Reuters in Shanghai

(Reuters) -AstraZeneca said a "meaningful proportion" of its shareholders voted against CEO Pascal Soriot's improved pay package on Tuesday, exposing a rift as the drugmaker deals with problems surrounding its COVID-19 vaccine.

At its annual investor meeting, 60.19% of votes cast were in favour, AstraZeneca said, adding that it would "engage and listen to ensure investors' concerns regarding the approach to executive remuneration are understood."

Large corporations typically win about 90% support for their pay in annual advisory votes, compensation consultants say, making narrow-win results such as AstraZeneca's effectively a call to review the programme and talk to shareholders.

Shares in London-listed AstraZeneca slipped 1.1% after the vote, which comes as the drugmaker faces a second European Union legal move over delayed deliveries of its COVID-19 vaccine and concerns over rare blood clots.

The new pay policy takes Soriot's maximum annual bonus for 2021 to 2.5 times his base salary, up from twice his salary, and makes him eligible for long-term share awards worth as much as 6.5 times his salary, up from 5.5 times.

His new package puts him among the best paid European pharmaceutical bosses but still lags Johnson & Johnson CEO Alex Gorsky's near-$30 million pay plan which was approved https://www.reuters.com/article/us-johnson-johnson-ceo-pay-idCAKBN2C927M by shareholders last month, also after some opposition.

Soriot, who has been in charge of AstraZeneca since 2012, told The Times in a 2018 interview https://www.thetimes.co.uk/article/salary-size-matters-says-astra-zeneca-boss-on-9-4m-vg9c7hm2t that he found it annoying to be the lowest-paid CEO in the industry. His package has since jumped almost 50% from its level in 2017.

Soriot's total pay package for 2020 of 15.4 million pounds ($21.7 million) was roughly unchanged from 2019. Most of that comprised bonuses and long-term share awards on top of a base salary of 1.3 million pounds.

Shareholder advisory groups ISS, Glass Lewis and PIRC all recommended that investors vote against Soriot's pay increase.

AstraZeneca recognised remuneration was "a sensitive matter" during the pandemic but noted its contributions to tackling the crisis and the scale and scope of what Soriot and chief financial officer Marc Dunoyer were being asked to deliver.

The company has pledged not to make any profit from its COVID-19 vaccine during the pandemic and also not from low income countries thereafter.

"The Board considered it appropriate to take another step to address their market pay positioning in order to retain and incentivise them; and enable succession planning," it said.

Soriot has driven a change in AstraZeneca's fortunes by betting on newer products while thwarting a 2014 bid by Pfizer. AstraZeneca's oncology drug business, in particular, is thriving as its not-for-profit pandemic vaccine is distributed.

In a separate meeting, AstraZeneca shareholders approved its planned $39 billion takeover of U.S. group Alexion.

(Reporting by Pushkala Aripaka in Bengaluru and Ludwig Burger in Frankfurt; Additional reporting by Ross Kerber; Editing by Alexander Smith)

By Pushkala Aripaka and Ludwig Burger


© Reuters 2021
All news about ALEXION PHARMACEUTICALS, INC.
06/16Argenx's drug effective against muscle-weakening disease myasthenia gravis
RE
06/14ALEXION PHARMACEUTICALS  : Caelum and Alexion Present Additional Phase 2 Data Re..
AQ
06/11ALEXION PHARMACEUTICALS  : Caelum and Alexion Present Additional Phase 2 Data Re..
BU
06/09INSIDER TRENDS : Insider at Alexion Pharmaceuticals Disposes of Shares for Tax S..
MT
06/09INSIDER TRENDS : Insider at Alexion Pharmaceuticals Makes Tax Sale Interrupting ..
MT
06/09INSIDER TRENDS : Insider at Alexion Pharmaceuticals Sells Stock for Taxes Interr..
MT
06/07ALEXION PHARMACEUTICALS  : Gets FDA Nod To Use Ultomiris to Treat Rare Blood Dis..
MT
06/07ALEXION PHARMACEUTICALS  :  Alexion Announces FDA Approval of ULTOMIRIS® (ravuli..
BU
06/07ALEXION PHARMACEUTICALS  : AstraZeneca appoints Aradhana Sarin as new Chief Fina..
AQ
06/04Health Care Up Amid Drug Developments -- Health Care Roundup
DJ
More news
Financials (USD)
Sales 2021 6 650 M - -
Net income 2021 2 498 M - -
Net cash 2021 2 566 M - -
P/E ratio 2021 16,2x
Yield 2021 -
Capitalization 39 936 M 39 936 M -
EV / Sales 2021 5,62x
EV / Sales 2022 4,94x
Nbr of Employees 3 837
Free-Float 90,9%
Chart ALEXION PHARMACEUTICALS, INC.
Duration : Period :
Alexion Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALEXION PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 19
Average target price 174,88 $
Last Close Price 180,69 $
Spread / Highest target 13,5%
Spread / Average Target -3,22%
Spread / Lowest Target -22,5%
EPS Revisions
Managers and Directors
NameTitle
Ludwig N. Hantson Chief Executive Officer & Director
Aradhana Sarin Chief Financial Officer & Executive Vice President
David Richard Brennan Chairman
John J. Orloff Executive VP, Head-Research & Development
George Llado Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ALEXION PHARMACEUTICALS, INC.15.65%39 936
CSL LIMITED7.89%104 078
WUXI BIOLOGICS (CAYMAN) INC.28.50%71 827
BIOGEN INC.58.64%58 481
SAMSUNG BIOLOGICS CO.,LTD.1.21%48 692
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.21.49%44 555